1. Introduction
===============

The chemical investigations on soft corals of the genus *Cladiella* and *Klyxum* \[[@B1-marinedrugs-12-02446],[@B2-marinedrugs-12-02446],[@B3-marinedrugs-12-02446],[@B4-marinedrugs-12-02446],[@B5-marinedrugs-12-02446],[@B6-marinedrugs-12-02446],[@B7-marinedrugs-12-02446],[@B8-marinedrugs-12-02446],[@B9-marinedrugs-12-02446],[@B10-marinedrugs-12-02446],[@B11-marinedrugs-12-02446],[@B12-marinedrugs-12-02446],[@B13-marinedrugs-12-02446],[@B14-marinedrugs-12-02446],[@B15-marinedrugs-12-02446],[@B16-marinedrugs-12-02446],[@B17-marinedrugs-12-02446],[@B18-marinedrugs-12-02446],[@B19-marinedrugs-12-02446],[@B20-marinedrugs-12-02446],[@B21-marinedrugs-12-02446],[@B22-marinedrugs-12-02446],[@B23-marinedrugs-12-02446],[@B24-marinedrugs-12-02446],[@B25-marinedrugs-12-02446],[@B26-marinedrugs-12-02446],[@B27-marinedrugs-12-02446],[@B28-marinedrugs-12-02446],[@B29-marinedrugs-12-02446],[@B30-marinedrugs-12-02446]\] have afforded several eunicellin-based diterpenoids, of which many have been shown to exhibit interesting bioactivities \[[@B8-marinedrugs-12-02446],[@B10-marinedrugs-12-02446],[@B11-marinedrugs-12-02446],[@B12-marinedrugs-12-02446],[@B13-marinedrugs-12-02446],[@B14-marinedrugs-12-02446],[@B15-marinedrugs-12-02446],[@B16-marinedrugs-12-02446],[@B17-marinedrugs-12-02446],[@B18-marinedrugs-12-02446],[@B19-marinedrugs-12-02446],[@B20-marinedrugs-12-02446],[@B21-marinedrugs-12-02446],[@B22-marinedrugs-12-02446],[@B23-marinedrugs-12-02446],[@B24-marinedrugs-12-02446],[@B25-marinedrugs-12-02446],[@B26-marinedrugs-12-02446],[@B27-marinedrugs-12-02446],[@B28-marinedrugs-12-02446],[@B29-marinedrugs-12-02446],[@B30-marinedrugs-12-02446]\]. Our recent chemical study of a Taiwanese soft coral *Cladiella* *hirsuta* has led to the discovery of 13 eunicellin-based diterpenoids hirsutalins A--M \[[@B29-marinedrugs-12-02446],[@B30-marinedrugs-12-02446]\] and seven steroids hirsutosterols A--G \[[@B31-marinedrugs-12-02446]\] some of which have been found to possess cytotoxic \[[@B29-marinedrugs-12-02446]\] and anti-inflammatory activities \[[@B29-marinedrugs-12-02446],[@B30-marinedrugs-12-02446]\]. In this paper we further report the isolation of five new eunicellin-based compounds, hirsutalins N--R ([Chart 1](#marinedrugs-12-02446-f004){ref-type="fig"}), along with two known compounds, (1*R*\*,2*R*\*,3*R*\*,6*S*\*,7*S*\*,9*R*\*,10*R*\*,14*R*\*)-3-butanoyloxycladiell-11(17)-en-6,7-diol (**6**) \[[@B6-marinedrugs-12-02446]\], and hirsutalin E (**7**) \[[@B29-marinedrugs-12-02446]\] from *C*. *hirsuta* ([Chart 2](#marinedrugs-12-02446-f005){ref-type="fig"}). The structures of new compounds were determined by extensive spectroscopic analysis. Cytotoxicity of **1**--**7** against a limited panel of cancer cell lines and their anti-inflammatory activity, determined by their ability to inhibit the generation of super oxide anion and elastase release in *N*-formyl-methionyl-leucylphenylalanine/cytochalasin B(fMLP/CB)-induced human neutrophiles, were studied in order to discover bioactive compounds for future new drug development.

![Structures of metabolites **1**--**5**.](marinedrugs-12-02446-g004){#marinedrugs-12-02446-f004}

![Structures of metabolites **6** and **7**.](marinedrugs-12-02446-g005){#marinedrugs-12-02446-f005}

2. Results and Discussion
=========================

Hirsutalin N (**1**) was isolated as a colorless oil. The HRESIMS (*m/z* 461.2518) of **1** established a molecular formula of C~24~H~38~O~7~. The IR spectrum of **1** showed the presence of hydroxy and carbonyl groups from absorptions at 3451 and 1733 cm^−1^, respectively. The ^13^C NMR of **1** exhibited 24 carbon signals as expected which were found to be similar to these of a known metabolite hirsutalin I (**8**, [Chart 3](#marinedrugs-12-02446-f006){ref-type="fig"}) \[[@B30-marinedrugs-12-02446]\], the difference being that the hydroxymethyl group attached at C-18 in hirsutalin I was replaced by a methyl group in **1**. This was confirmed by ^1^H NMR spectrum of **1** which shows the presence of two isopropyl methyls at δ 0.73 (d, *J* = 7.2 Hz) and 0.97 (d, *J* = 7.2 Hz) ([Table 1](#marinedrugs-12-02446-t001){ref-type="table"}). Also, NMR data revealed that the *n*-butanoyloxy group at C-3 in **8** was replaced by an acetoxy group in **1**. Key HMBC correlations from H-2 to C-6; H-1, H~2~-8, and H-10 to C-9; H~3~-15 to C-2, C-3 and C-4; H~3~-16 to C-6, C-7 and C-8; H~3~-17 to C-10, C-11 and C-12; and both H~3~-19 and H~3~-20 to C-14 and C-18, permitted the assembly of the carbon skeleton of **1**. Based on above results and HMBC correlations ([Figure 1](#marinedrugs-12-02446-f001){ref-type="fig"}), the planar structure of **1** was established. Further, comparison of the NOE correlations of **1** ([Figure 2](#marinedrugs-12-02446-f002){ref-type="fig"}) with those of hirsutalin I, the relative configuration of **1** was thus determined to be the same.

marinedrugs-12-02446-t001_Table 1

###### 

NMR spectroscopic data for hirsutalins N--P (**1**--**3**).

  1          2                      3                                                                                      
  ---------- ---------------------- ---------------------- ---------------- ---------------------- ----------------------- ---------------
  1          49.6, CH               2.55, dd (12.0, 4.4)   41.4, CH         2.25, m                41.9, CH                2.18, m
  2          78.0, CH               3.80, s                91.3, CH         3.56, s                90.8, CH                3.56, s
  3          81.3, C                \-                     74.0, C          \-                     74.7, C                 \-
  4          27.7, CH~2~            1.36, m                34.9, CH~2~      1.75, m                41.0, CH~2~             1.83, m
  \-         2.92, dd (11.8, 4.4)   \-                     \-               \-                     \-                      
  5          20.6, CH~2~            1.34, m                32.0, CH~2~      1.99, m                25.7, CH~2~             1.98, m
  \-         1.66, m                \-                     \-               \-                     \-                      
  6          80.4, CH               3.82, dd (11.4, 6.0)   76.4, CH         5.19, dd (12.0, 6.0)   90.8, CH                4.07, m
  7          85.4, C                \-                     149.0, C         \-                     76.6, C                 \-
  8          49.5, CH~2~            2.00, d (12.0)         41.4, CH~2~      3.12, dd (13.6, 6.0)   47.0, CH~2~             1.73, m
  \-         2.78, d (12.0)         \-                     2.47, d (13.6)   \-                     2.30, dd (12.8, 11.6)   
  9          211.4, C               \-                     78.3, CH         4.09, dd (11.2, 6.0)   75.6, CH                4.07, m
  10         55.2, CH               4.14, dd (4.4, 2.0)    46.4, CH         2.95, dd (11.2, 7.2)   54.4, CH                2.82, t (7.6)
  11         83.3, C                \-                     82.3, C          \-                     82.9, C                 \-
  12         31.4, CH~2~            2.10, m                32.5, CH~2~      1.43, m                30.5, CH~2~             1.38, m
  \-         2.24, m                \-                     2.24, m          \-                     2.40, m                 
  13         19.3, CH~2~            1.61, m                18.2, CH~2~      1.34, m                17.7, CH~2~             1.20, m
  \-         1.25, m                \-                     1.45, m          \-                     1.40, m                 
  14         36.5, CH               1.98, m                42.8, CH         1.20, m                42.6, CH                1.22, m
  15         23.6, CH~3~            1.53, s                27.4, CH~3~      1.19, s                30.3, CH~3~             1.16, s
  16         22.9, CH~3~            1.13, s                118.3, CH~2~     5.29, s                23.8, CH~3~             1.16, s
  \-         \-                     \-                     5.53, s          \-                     \-                      
  17         24.3, CH~3~            1.45, s                25.5, CH~3~      1.52, s                24.5, CH~3~             1.46, s
  18         27.2, CH               1.87, m                27.9, CH         1.80, m                29.1, CH                1.71, m
  19         14.5, CH~3~            0.73, d (7.2)          15.0, CH~3~      0.78, d (6.8)          15.0, CH~3~             0.78, d (6.8)
  20         21.7, CH~3~            0.97, d (7.2)          21.8, CH~3~      0.94, d (6.8)          21.8, CH~3~             0.94, d (6.8)
  3-OAc      22.4, CH~3~            2.00, s                \-               \-                     \-                      \-
  169.7, C   \-                     \-                     \-               \-                     \-                      
  11-OAc     22.3, CH~3~            2.19, s                22.6, CH~3~      2.00, s                22.6, CH~3~             2.00, s
  170.1, C   \-                     170.3, C               \-               170.2, C               \-                      
  6-OAc      \-                     \-                     21.4, CH~3~      1.99, s                \-                      \-
  \-         \-                     170.5, C               \-               \-                     \-                      
  6-OMe      \-                     \-                     \-               \-                     57.1, CH~3~             3.37, s

^a^ Spectra recorded at 100 MHz in CDCl~3~; ^b^ multiplicity deduced from DEPT; ^c^ spectra recorded at 400 MHz in CDCl~3~.

![COSY and HMBC correlations for **1**, **2**, **4** and **5**.](marinedrugs-12-02446-g001){#marinedrugs-12-02446-f001}

![Key NOESY correlations for 1.](marinedrugs-12-02446-g002){#marinedrugs-12-02446-f002}

Hirsutalin O (**2**) was also afforded as a colorless oil. Compound **2** has a molecular formula C~24~H~38~O~6~, as determined by HRESIMS. In comparing NMR data of **2** with those of the known compound simplexin A (**9**, [Chart 3](#marinedrugs-12-02446-f006){ref-type="fig"}) \[[@B11-marinedrugs-12-02446]\], it was found that the *n*-butanoyloxy group at C-3 and the hydroxy group at C-6 in simplexin A (**9**) were replaced by a hydroxy group and acetoxy group in **2**, respectively, as confirmed by the downfield shift of C-3 (δ~C~ 81.3) of **1**, relative to that of **2** (δ~C~ 74.0), and the HMBC connectivity from H-6 (δ 5.19) to the carbonyl carbon resonating at δ 170.5 (C) ([Table 1](#marinedrugs-12-02446-t001){ref-type="table"}). The relative configuration of **2** was confirmed to be the same as that of **9** by analysis of NOE correlations ([Figure 3](#marinedrugs-12-02446-f003){ref-type="fig"}).

![Key NOESY correlations for 2.](marinedrugs-12-02446-g003){#marinedrugs-12-02446-f003}

The new eunicellin, hirsutalin P (**3**), has a molecular formula C~23~H~40~O~6~ as determined by HRESIMS. The spectroscopic data (IR, ^1^H NMR, and ^13^C NMR) of **3** were similar to those of a known one, klysimplex G (**10**, [Chart 3](#marinedrugs-12-02446-f006){ref-type="fig"}) \[[@B12-marinedrugs-12-02446]\], except that the acetoxy group at C-3 and the hydroxy group at C-6 in **10** were replaced by a hydroxy group and methoxy group, respectively, in **3**. The similar ^1^H NMR data and the analysis of NOE correlations of **3** further revealed the same relative configuration of both compounds. Thus, the structure of **3** was established.

![Structures of known compounds **8**--**11**.](marinedrugs-12-02446-g006){#marinedrugs-12-02446-f006}

Hirsutalin Q (**4**) was obtained as a colorless oil and exhibited a molecular formula C~22~H~36~O~5~. IR absorptions of **4** showed the presence of hydroxy and carbonyl groups at 3421 and 1724 cm^−1^, respectively. The NMR spectroscopic data revealed the presence of a trisubstituted double bond (δ~H~ 5.28, s, 1H; δ~C~ 128.4, CH and 139.4, C) ([Table 2](#marinedrugs-12-02446-t002){ref-type="table"}). One ester carbonyl (δ~C~ 170.2) was assigned from the ^13^C NMR spectrum and was HMBC correlated with an acetate methyl (δ~H~ 1.99 s). The chemical shift of H~3~-15 at *δ* 1.18 indicated the presence of a hydroxy group substitution at C-3, the same as that in compounds **2** and **3**. The presence of an acetoxy group at C-11 could be seen from the more downfield shift of H~3~-17 (δ 1.53), in comparison with that of H~3~-15 (δ 1.18). The planar structure of metabolite **1** was elucidated by analysis of COSY and HMBC correlations ([Figure 1](#marinedrugs-12-02446-f001){ref-type="fig"}). The *Z* geometry of the double bond at C-7 and C-8 was evidenced by the presence of NOE correlation between H-8 and H~3~-16. In the NOESY spectrum of **4**, observation of the NOE correlation between H-1 with H-10 suggested that H-1 and H-10 are β-oriented. Also, correlations between H-2 with both H-14 and H~3~-15; H-9 with both H-14 and H~3~-17; and H-6 with H~3~-15 suggested that all of H-2, H-6, H-9, H-14, H~3~-15 and H~3~-17 are α-oriented. Thus, the structure of diterpenoid **4** was established.

A structurally-related metabolite, hirsutalin R (**5**), was also isolated as a colorless oil with a molecular formula of C~28~H~42~O~7~. Two ester carbonyl carbons (δ~C~ 169.0 and 173.5) were correlated in the HMBC spectrum with the methine proton (H-2′, δ~H~ 4.76 t, *J* = 6.8 Hz) of a 2-butyryloxybutanoate unit. Moreover, the ^13^C NMR spectroscopic data ([Table 2](#marinedrugs-12-02446-t002){ref-type="table"}) of **5** showed the presence of two 1, 1-disubstituted carbon--carbon double bonds (δ~C~ 147.7 (C) and 118.4 (CH~2~); 145.2 (C) and 111.6 (CH~2~)). Comparison of the NMR data of **5** with those of hirsutalin C (**11**, [Chart 3](#marinedrugs-12-02446-f006){ref-type="fig"}) \[[@B29-marinedrugs-12-02446]\] revealed that the only difference between both compounds is the replacement of the hydroxy group in hirsutalin C by a ketone (δ~C~ 206.5) at C-6 in **5**. The absolute configuration of hirsutalin A \[[@B29-marinedrugs-12-02446]\] and hirsutalin J \[[@B30-marinedrugs-12-02446]\] have been completely assigned based on NOE correlations and Mosher's method. Compounds **1**--**5** are likely in the same enantiomeric series as hirsutalin A and hirsutalin J, based on a shared biosynthetic pathway. Thus, these compounds are suggested to possess the absolute configurations as shown in formula **1**--**5**.

marinedrugs-12-02446-t002_Table 2

###### 

NMR spectroscopic data for hirsutalins Q and R (**4** and **5**).

  4                        5                                                
  ------------------------ ------------- ------------------- -------------- ----------------------
  1                        40.9, CH      2.35, m             45.0, CH       2.25, m
  2                        90.8, CH      3.57, s             90.8, CH       3.69, s
  3                        74.7, C       \-                  86.0, C        \-
  4                        37.2, CH~2~   1.83, m;            32.2, CH~2~    2.12, m
  5                        25.7, CH~2~   1.81, m             36.4, CH~2~    2.68, m
  \-                       1.90, m       \-                  2.28, m        
  6                        70.6, CH      5.48, d (8.8) ^d^   206.5, CH      \-
  7                        139.4, C      \-                  147.7, C       \-
  8                        128.4, CH     5.28, s             37.3, CH~2~    3.22, dd (13.2, 5.6)
  \-                       \-            \-                  2.34, m        
  9                        78.6, CH      4.47, d (6.0)       78.4, CH       4.08, m
  10                       54.9, CH      2.70, t (7.2)       48.8, CH       3.08, dd (9.6, 7.6)
  11                       83.0, C       \-                  145.2 , C      \-
  12                       30.4, CH~2~   1.32, m             31.2, CH~2~    2.08, m
  \-                       1.52, m       \-                  2.27, m        
  13                       18.4, CH~2~   1.35, m             25.9, CH~2~    1.10, m
  \-                       1.45, m       \-                  1.65, m        
  14                       42.1, CH      1.26, m             37.5, CH       1.66, m
  15                       27.7, CH~3~   1.18, s             22.7, CH~3~    1.48, s
  16                       17.9, CH~3~   1.79, s             118.4, CH~2~   5.27, s
  \-                       \-            \-                  5.62, s        
  17                       23.7, CH~3~   1.53, s             111.6, CH~2~   4.72, s
  \-                       \-            \-                  4.85, s        
  18                       29.2, CH      1.72, m             36.4, CH       1.78, m
  19                       16.5, CH~3~   0.83, d (7.2)       16.3, CH~3~    0.79, d (7.2)
  20                       21.9, CH~3~   0.96, d (7.2)       66.4, CH~2~    3.52, d (7.2)
  11-OAc                   22.6, CH~3~   1.99, s             \-             \-
  170.2, C                 \-            \-                  \-             
  2-butanoyloxybutanoate   \-            \-                  \-             \-
  1′                       \-            \-                  169.0, C       \-
  2′                       \-            \-                  73.6, CH       4.76, t (6.8)
  3′                       \-            \-                  24.5, CH~2~    1.83, m
  4′                       \-            \-                  9.7, CH~3~     1.03, t (7.2)
  1′′                      \-            \-                  173.5, C       \-
  2′′                      \-            \-                  35.8, CH~2~    2.40, m
  3′′                      \-            \-                  18.3, CH~2~    1.66, m
  4′′                      \-            \-                  13.6, CH~3~    0.98, t (7.2)

^a^ Spectra recorded at 100 MHz in CDCl~3~; ^b^ Multiplicity deduced from DEPT; ^c^ Spectra recorded at 400 MHz in CDCl~3~.

Cytotoxicity of compounds **1**--**7** against the proliferation of a limited panel of cancer cell lines, including P388 (murine leukemia), K562 (human erythro myeloblastoid leukemia), A549 (human lung adenocarcinoma), and HT-29 (human colon adenocarcinoma), was evaluated. Compound **5** was found to exhibit cytotoxicity toward P388 and K562 cell lines with IC~50~ values of 13.8 and 36.3 μM ([Table 3](#marinedrugs-12-02446-t003){ref-type="table"}). Compound **7** displayed cytotoxicity toward A549 cell line with IC~50~ value of 37.2 μM. Other metabolites were found to be inactive against the four cancer cells. The neutrophil pro-inflammatory responses to compounds **1**--**7** were evaluated by suppressing *N*-formyl-methionyl-leucyl-phenylalanine/cytochalasin B (fMLP/CB)-induced superoxide anion (O~2~^•−^) generation and elastase release in human neutrophils, as shown in [Table 4](#marinedrugs-12-02446-t004){ref-type="table"}. At a concentration of 10 μg/mL, none of compounds were able to significantly reduce the expression of superoxide anion generation, relative to the control cells stimulated with fMLP/CB only. At the same concentration, compound **1** was found to significantly inhibit the elastase release (31.7% ± 3.2% inhibition) in the same fMLP/CB-stimulated neutrophils.

marinedrugs-12-02446-t003_Table 3

###### 

Cytotoxicity (IC~50~ μM) of compounds **5** and **7**.

  Compound         P388   K562   HT-29      A-549
  ---------------- ------ ------ ---------- -------
  **5**            13.8   36.3   (--) ^a^   (--)
  **7**            (--)   (--)   (--)       37.2
  5-Fluorouracil   8.5    24.6   20.8       38.5

^a^ IC~50~ \> 40 μM.

marinedrugs-12-02446-t004_Table 4

###### 

Effect of compounds **1**--**7** on superoxide anion generation and elastase release in fMLP/CB-induced human neutrophils at 10 μg/mL.

  Compounds   Superoxide Anion   Elastase Release                       
  ----------- ------------------ ------------------ ------ ------------ --------
  1           \>10               1.0 ± 5.5          \>10   31.7 ± 3.2   \*\*\*
  2           \>10               9.6 ± 5.5          \>10   11.5 ± 5.0   \-
  3           \>10               1.7 ± 0.7          \>10   17.9 ± 6.9   \*
  4           \>10               6.1 ± 2.6          \>10   6.4 ± 2.4    \-
  5           \>10               6.5 ± 2.9          \>10   13.6 ± 4.9   \*
  6           \>10               1.0 ± 1.9          \>10   6.1 ± 5.6    \-
  7           \>10               4.2 ± 3.8          \>10   3.1 ± 6.9    \-

Percentage of inhibition (Inh %) at 10 μM concentration. Results are presented as mean ± S.E.M. (*n* = 3 or 4). \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001 compared with the control value. ^a^ Concentration necessary for 50% inhibition (IC~50~).

3. Experimental Section
=======================

3.1. General Experimental Procedures
------------------------------------

Silica gel (230--400 mesh, Merck, Darmstadt, Germany) was used for column chromatography. Precoated silica gel plates (Merck, Kieselgel 60 F-254, 0.2 mm) were used for analytical TLC. High-performance liquid chromatography was performed on a Hitachi L-7100 HPLC apparatus with a Hitachi L-2455 HPLC apparatus (Hitachi Ltd., Tokyo, Japan) with a Supelco C18 column (250 × 21.2 mm, 5 μm). NMR spectra were recorded on a Varian 400MR FT-NMR instrument (Varian Inc, Palo Alto, CA, USA) at 400 MHz for ^1^H and 100 MHz for ^13^C in CDCl~3~. LRMS and HRMS were obtained by ESI on a Bruker APEX II mass spectrometer (Bruker, Bremen, Germany). Optical rotations were measured on a JASCO P-1020 polarimeter. IR spectra were recorded on a JASCO FT/IR-4100 infrared spectrophotometer (Japan Spectroscopic Corporation, Tokyo, Japan).

3.2. Animal Material
--------------------

The animal *Cladiella* *hirsuta* was collected by hand using SCUBA off the coast of Sianglu Islet (23°32\' N, 119°38\' E) in the region of Penghu Islands, in June 2008, at a depth of 10 m, and was stored in a freezer until extraction. A voucher sample (PI-20080610-17) was deposited at the Department of Marine Biotechnology and Resources, National Sun Yat-sen University.

3.3. Extraction and Separation
------------------------------

The frozen bodies of *C.* *hirsuta* (3.1 kg, wet wt) were sliced and exhaustively extracted with acetone (3 × 10 L). The organic extract was concentrated to an aqueous suspension and was partitioned between ethyl acetate (EtOAc) and H~2~O. The EtOAc layer was dried with anhydrous Na~2~SO~4~. After removal of solvent in vacuo, the residue (32.8 g) was subjected to column chromatography on silica gel and eluted with EtOAc in *n*-hexane (0%--100% of EtOAc, gradient) and further with MeOH in EtOAc of increasing polarity to yield 25 fractions. Fraction 18, eluting with *n*-hexane--EtOAc (1:1), was rechromatographed over a Sephadex LH-20 column using acetone as the mobile phase to afford four subfractions (A1--A4). Subfractions A3 and A4 were combined and separated by reversed-phase HPLC (MeOH--H~2~O, 3:1 and 2:1) to afford compounds **4** (1.8 mg), **5** (1.4 mg), **6** (27.7 mg) and **7** (5.6 mg), respectively. Fraction 19, eluting with *n*-hexane--EtOAc (1:2), was rechromatographed over a Sephadex LH-20 column, using acetone as the mobile phase, to afford four subfractions (B1--B4). Subfractions B2 and B3 were combined and separated by reversed-phase HPLC (acetonitrile--H~2~O, 3:1 and 2:1) to afford compounds **1** (9.2 mg), **2** (4.0 mg), and **3** (1.8 mg), respectively.

Hirsutalin N (**1**): colorless oil; \[α\]^25^~D~ −98 (*c* 0.54, CHCl~3~); IR (neat) *v*~max~ 3451 and 1733 cm^−1^; ^13^C and ^1^H NMR data (400 MHz; CDCl~3~), see [Table 1](#marinedrugs-12-02446-t001){ref-type="table"}; ESIMS *m/z* 461 \[M + Na\]^+^; HRESIMS *m/z* 461.2518 \[M + Na\]^+^(calcd for C~24~H~38~O~7~Na, 461.2515) ([Supplementary Information, Figures S1--S3](#marinedrugs-12-02446-s001){ref-type="supplementary-material"}).

Hirsutalin O (**2**): colorless oil; \[α\]^25^~D~ −128 (*c* 0.68, CHCl~3~); IR (neat) *v*~max~ 3482 and 1729 cm^−1^; ^13^C and ^1^H NMR data (400 MHz; CDCl~3~), see [Table 1](#marinedrugs-12-02446-t001){ref-type="table"}; ESIMS *m/z* 445 \[M + Na\]^+^; HRESIMS *m/z* 445.2564 \[M + Na\]^+^(calcd for C24H38O6Na, 445.2566) ([Supplementary Information, Figures S4--S6](#marinedrugs-12-02446-s001){ref-type="supplementary-material"}).

Hirsutalin P (**3**): colorless oil; \[α\]^25^~D~ +27 (*c* 0.54, CHCl~3~); IR (neat) *v*~max~ 3426 and 1730 cm^−1^; ^13^C and ^1^H NMR data (400 MHz; CDCl~3~), see [Table 1](#marinedrugs-12-02446-t001){ref-type="table"}; ESIMS *m/z* 435 \[M + Na\]^+^; HRESIMS *m/z* 435.2720 \[M + Na\]^+^(calcd for C~23~H~40~O~6~Na, 435.2722) ([Supplementary Information, Figures S7--S9](#marinedrugs-12-02446-s001){ref-type="supplementary-material"}).

Hirsutalin Q (**4**): colorless oil; \[α\]^25^~D~ +12 (*c* 0.51, CHCl~3~); IR (neat) *v*~max~ 3421 and 1724 cm^−1^; ^13^C and ^1^H NMR data (400 MHz; CDCl~3~), see [Table 2](#marinedrugs-12-02446-t002){ref-type="table"}; ESIMS *m/z* 403 \[M + Na\]^+^; HRESIMS *m/z*403.2457 \[M + Na\]^+^(calcd for C22H36O5Na, 403.2460) ([Supplementary Information, Figures S10--S12](#marinedrugs-12-02446-s001){ref-type="supplementary-material"}).

Hirsutalin R (**5**): yellow oil; \[α\]^25^~D~ −18 (*c* 0.54, CHCl~3~); IR (neat) *v*~max~ 3437 and 1740 cm^−1^; ^13^C and ^1^H NMR data (400 MHz; CDCl~3~), see [Table 2](#marinedrugs-12-02446-t002){ref-type="table"}; ESIMS *m/z* 513 \[M + Na\]^+^; HRESIMS *m/z* 513.2831 \[M + Na\]^+^(calcd for C~28~H~42~O~7~Na, 513.2828) ([Supplementary Information, Figures S13--S15](#marinedrugs-12-02446-s001){ref-type="supplementary-material"}).

3.4. Cytotoxicity Testing
-------------------------

Cell lines were purchased from the American Type Culture Collection (ATCC). Cytotoxicity assays of compounds **1**--**7** were performed using the Alamar Blue assay \[[@B32-marinedrugs-12-02446],[@B33-marinedrugs-12-02446]\].

3.5. In Vitro Anti-Inflammatory Assay
-------------------------------------

Human neutrophils were obtained using dextran sedimentation and Ficoll centrifugation. Measurements of superoxide anion generation and elastase release were carried out according to previously described procedures. \[[@B34-marinedrugs-12-02446],[@B35-marinedrugs-12-02446]\]. LY294002, a phosphatidylinositol-3-kinase inhibitor, was used as a positive control for inhibition of superoxide anion generation and elastase release with IC~50~ 0.6 ± 0.1 and 1.2 ± 0.3 μg/mL \[[@B36-marinedrugs-12-02446]\].

4. Conclusions
==============

Five new eunicellin-type compounds, hirsutalins N--R (**1**--**5**) and two known eunicellin-type compounds (**6** and **7**), were discovered from the soft coral *C.* *hirsuta*. Compound **5** displayed cytotoxicity against the proliferation of P388 and K562 cancer cells possibly due to the presence of the α,β-unsaturated ketone group. Compound **1** was found to effectively inhibit the elastase release in FMLP/CB-induced human neutrophils.
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